Cargando…

Topical anesthesia therapy using lidocaine-loaded nanostructured lipid carriers: tocopheryl polyethylene glycol 1000 succinate-modified transdermal delivery system

PURPOSE: Transdermal drug delivery of local anesthetics using lipid nanoparticles could enhance lipophilic drugs permeation through the stratum corneum, improve drug diffusion to deeper skin, and exert good therapeutic effects. The purpose of this study was to engineer a Tocopheryl Polyethylene Glyc...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Xiangju, Sun, Ying, Li, Zhaoguo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6296185/
https://www.ncbi.nlm.nih.gov/pubmed/30587919
http://dx.doi.org/10.2147/DDDT.S187177
_version_ 1783381000002207744
author Zhao, Xiangju
Sun, Ying
Li, Zhaoguo
author_facet Zhao, Xiangju
Sun, Ying
Li, Zhaoguo
author_sort Zhao, Xiangju
collection PubMed
description PURPOSE: Transdermal drug delivery of local anesthetics using lipid nanoparticles could enhance lipophilic drugs permeation through the stratum corneum, improve drug diffusion to deeper skin, and exert good therapeutic effects. The purpose of this study was to engineer a Tocopheryl Polyethylene Glycol 1000 Succinate (TPGS)-modified cationic nanostructured lipid carriers (NLC) for the delivery of lidocaine (LID; TPGS/LID-NLC). MATERIALS AND METHODS: TPGS/LID-NLC was prepared by solvent diffusion method. The particle size, polydispersity index, zeta potential, drug entrapment efficiency, drug loading, stability, drug release, and cytotoxicity were tested to evaluate the basic characters of NLC. In vitro skin permeation and in vivo anesthesia effect in an animal model were further investigated to determine the therapeutic efficiency of the system. RESULTS: TPGS/LID-NLC had a particle size of 167.6±4.3 nm, a zeta potential of +21.2±2.3 mV, an entrapment efficiency of 85.9%±3.1%, and a drug loading of 11.5%±0.9%. A sustained release pattern was achieved by TPGS/LID-NLC, with 81.2% of LID released at 72 hours. In vitro permeation study showed that the steady-state fluxes (J(ss)), permeability coefficient (Kp), and cumulative drug permeation Q(n) at 72 hours (Q(72)) of TPGS/LID-NLC were 15.6±1.8 µg/cm(2)/hour, 10.3±0.9 cm/hour (×10(−3)), and 547.5±23.6 µg/cm(2), respectively, which were significantly higher than the nonmodified NLC and free drug groups. In vivo anesthesia effect of TPGS/LID-NLC was the most remarkable and long acting among the formulations tested, which could be concluded by the most considerable maximum possible effect from 10 to 120 minutes during the whole research. CONCLUSION: The most prominent in vitro permeation efficiency and in vivo anesthetic effect of TPGS/LID-NLC could be the evidence that TPGS-modified NLC could function as a promising drug delivery system for prolonged and efficient local anesthetic therapy.
format Online
Article
Text
id pubmed-6296185
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-62961852018-12-26 Topical anesthesia therapy using lidocaine-loaded nanostructured lipid carriers: tocopheryl polyethylene glycol 1000 succinate-modified transdermal delivery system Zhao, Xiangju Sun, Ying Li, Zhaoguo Drug Des Devel Ther Original Research PURPOSE: Transdermal drug delivery of local anesthetics using lipid nanoparticles could enhance lipophilic drugs permeation through the stratum corneum, improve drug diffusion to deeper skin, and exert good therapeutic effects. The purpose of this study was to engineer a Tocopheryl Polyethylene Glycol 1000 Succinate (TPGS)-modified cationic nanostructured lipid carriers (NLC) for the delivery of lidocaine (LID; TPGS/LID-NLC). MATERIALS AND METHODS: TPGS/LID-NLC was prepared by solvent diffusion method. The particle size, polydispersity index, zeta potential, drug entrapment efficiency, drug loading, stability, drug release, and cytotoxicity were tested to evaluate the basic characters of NLC. In vitro skin permeation and in vivo anesthesia effect in an animal model were further investigated to determine the therapeutic efficiency of the system. RESULTS: TPGS/LID-NLC had a particle size of 167.6±4.3 nm, a zeta potential of +21.2±2.3 mV, an entrapment efficiency of 85.9%±3.1%, and a drug loading of 11.5%±0.9%. A sustained release pattern was achieved by TPGS/LID-NLC, with 81.2% of LID released at 72 hours. In vitro permeation study showed that the steady-state fluxes (J(ss)), permeability coefficient (Kp), and cumulative drug permeation Q(n) at 72 hours (Q(72)) of TPGS/LID-NLC were 15.6±1.8 µg/cm(2)/hour, 10.3±0.9 cm/hour (×10(−3)), and 547.5±23.6 µg/cm(2), respectively, which were significantly higher than the nonmodified NLC and free drug groups. In vivo anesthesia effect of TPGS/LID-NLC was the most remarkable and long acting among the formulations tested, which could be concluded by the most considerable maximum possible effect from 10 to 120 minutes during the whole research. CONCLUSION: The most prominent in vitro permeation efficiency and in vivo anesthetic effect of TPGS/LID-NLC could be the evidence that TPGS-modified NLC could function as a promising drug delivery system for prolonged and efficient local anesthetic therapy. Dove Medical Press 2018-12-13 /pmc/articles/PMC6296185/ /pubmed/30587919 http://dx.doi.org/10.2147/DDDT.S187177 Text en © 2018 Zhao et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Zhao, Xiangju
Sun, Ying
Li, Zhaoguo
Topical anesthesia therapy using lidocaine-loaded nanostructured lipid carriers: tocopheryl polyethylene glycol 1000 succinate-modified transdermal delivery system
title Topical anesthesia therapy using lidocaine-loaded nanostructured lipid carriers: tocopheryl polyethylene glycol 1000 succinate-modified transdermal delivery system
title_full Topical anesthesia therapy using lidocaine-loaded nanostructured lipid carriers: tocopheryl polyethylene glycol 1000 succinate-modified transdermal delivery system
title_fullStr Topical anesthesia therapy using lidocaine-loaded nanostructured lipid carriers: tocopheryl polyethylene glycol 1000 succinate-modified transdermal delivery system
title_full_unstemmed Topical anesthesia therapy using lidocaine-loaded nanostructured lipid carriers: tocopheryl polyethylene glycol 1000 succinate-modified transdermal delivery system
title_short Topical anesthesia therapy using lidocaine-loaded nanostructured lipid carriers: tocopheryl polyethylene glycol 1000 succinate-modified transdermal delivery system
title_sort topical anesthesia therapy using lidocaine-loaded nanostructured lipid carriers: tocopheryl polyethylene glycol 1000 succinate-modified transdermal delivery system
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6296185/
https://www.ncbi.nlm.nih.gov/pubmed/30587919
http://dx.doi.org/10.2147/DDDT.S187177
work_keys_str_mv AT zhaoxiangju topicalanesthesiatherapyusinglidocaineloadednanostructuredlipidcarrierstocopherylpolyethyleneglycol1000succinatemodifiedtransdermaldeliverysystem
AT sunying topicalanesthesiatherapyusinglidocaineloadednanostructuredlipidcarrierstocopherylpolyethyleneglycol1000succinatemodifiedtransdermaldeliverysystem
AT lizhaoguo topicalanesthesiatherapyusinglidocaineloadednanostructuredlipidcarrierstocopherylpolyethyleneglycol1000succinatemodifiedtransdermaldeliverysystem